Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Resveratrol Provides No Health Benefits to Healthy, Middle-Aged Women

By LabMedica International staff writers
Posted on 08 Nov 2012
A recent study found that resveratrol, an ingredient in red wine thought to improve insulin sensitivity, reduce risk of heart disease and increase longevity, displayed no health benefits in a population of healthy, post-menopausal women.

Resveratrol (trans-3,5,4'-trihydroxystilbene), a compound found largely in the skins of red grapes, is a component of Ko-jo-kon, a form of oriental medicine used to treat diseases of the blood vessels, heart, and liver. More...
It came to scientific attention during the mid-1990s as a possible explanation for the "French Paradox," i.e., the low incidence of heart disease among the French, who eat a relatively high-fat diet. Since then, it has been promoted by manufacturers and examined by scientific researchers as an antioxidant, an anticancer agent, and a phytoestrogen.

In a study published in the October 25, 2012, online edition of the journal Cell Metabolism investigators at the Washington University School of Medicine (St. Louis, MO, USA) conducted a randomized, double blind, placebo-controlled trial to evaluate the metabolic effects of 12 weeks of resveratrol supplementation in nonobese, postmenopausal women with normal glucose tolerance. The group comprised 29 women who did not have type II diabetes and were reasonably healthy. Half the group took an over-the-counter resveratrol supplement (the equivalent of eight liters of red wine per day) while the others received a placebo.

Results revealed that while resveratrol supplementation increased plasma resveratrol concentration, it did not change body composition, resting metabolic rate, plasma lipids, or inflammatory markers. Resveratrol did not increase liver, skeletal muscle, or adipose tissue insulin sensitivity. Furthermore, resveratrol did not affect its putative molecular targets in fat or muscle in nonobese women.

“Resveratrol supplements have become popular because studies in cell systems and rodents show that resveratrol can improve metabolic function and prevent or reverse certain health problems like diabetes, heart disease, and even cancer,” said senior investigator Dr. Samuel Klein, professor of medicine and nutritional science at the Washington University School of Medicine. “But our data demonstrate that resveratrol supplementation does not have metabolic benefits in relatively healthy, middle-aged women.”

“The purpose of our study was not to identify the active ingredient in red wine that improves health but to determine whether supplementation with resveratrol has independent, metabolic effects in relatively healthy people,” said Dr. Klein. “We were unable to detect a metabolic benefit of resveratrol supplementation in our study population, but this does not preclude the possibility that resveratrol could have a synergistic effect when combined with other compounds in red wine.”

Related Links:
Washington University School of Medicine




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.